ATE402698T1 - Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten - Google Patents

Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten

Info

Publication number
ATE402698T1
ATE402698T1 AT98965293T AT98965293T ATE402698T1 AT E402698 T1 ATE402698 T1 AT E402698T1 AT 98965293 T AT98965293 T AT 98965293T AT 98965293 T AT98965293 T AT 98965293T AT E402698 T1 ATE402698 T1 AT E402698T1
Authority
AT
Austria
Prior art keywords
ppar
skin diseases
treat skin
gamma activators
gamma
Prior art date
Application number
AT98965293T
Other languages
English (en)
Inventor
Michel Rivier
Irina Safonova
Serge Michel
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Application granted granted Critical
Publication of ATE402698T1 publication Critical patent/ATE402698T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT98965293T 1997-12-31 1998-12-28 Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten ATE402698T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9716808A FR2773075B1 (fr) 1997-12-31 1997-12-31 Utilisation d'activateurs de ppar-gamma en dermatologie

Publications (1)

Publication Number Publication Date
ATE402698T1 true ATE402698T1 (de) 2008-08-15

Family

ID=9515385

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98965293T ATE402698T1 (de) 1997-12-31 1998-12-28 Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten

Country Status (13)

Country Link
US (1) US6403656B1 (de)
EP (1) EP1041977B1 (de)
JP (1) JP3773790B2 (de)
AT (1) ATE402698T1 (de)
AU (1) AU745187B2 (de)
BR (1) BR9815340A (de)
CA (1) CA2314607C (de)
DE (1) DE69839815D1 (de)
ES (1) ES2310019T3 (de)
FR (1) FR2773075B1 (de)
NO (1) NO325171B1 (de)
NZ (1) NZ505089A (de)
WO (1) WO1999034783A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908647D0 (en) * 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US20040034067A1 (en) * 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
WO2002009639A2 (en) * 2000-07-31 2002-02-07 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
DE50012500D1 (de) * 2000-11-09 2006-05-18 Phenion Gmbh & Co Kg Ppar-alpha,beta-aktivatoren zur behandlung von alopecia areata und vitiligo
JP2004532230A (ja) * 2001-04-30 2004-10-21 アラクノーバ・セラピューティックス・リミテッド Ｐｐａｒ−ガンマアクチベーターを使用する瘢痕化および関連状態の処置
DE10204398A1 (de) * 2002-02-04 2003-08-14 Univ Goettingen Georg August Neue Verwendung von Liganden der 'Peroxisome Proliferator-Activated receptors'(PPAR)
US20040115637A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of PPAR-alpha expression
GB0303600D0 (en) * 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
DK1651161T3 (da) * 2003-08-07 2012-01-30 Healor Ltd Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
JP2007513173A (ja) * 2003-12-03 2007-05-24 スミスクライン・ビーチャム・コーポレイション ロシグリタゾンを用いる乾癬の治療
JP4556511B2 (ja) * 2004-06-25 2010-10-06 ソニー株式会社 １５ｄ−ＰＧＪ２、及び、１５ｄ−ＰＧＪ２を用いた方法
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
WO2007026356A2 (en) * 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
KR100702415B1 (ko) * 2006-03-03 2007-04-09 안웅식 올리고 핵산 탐침 비드 어레이를 이용한 인유두종바이러스검출 키트 및 방법
US20100310542A1 (en) * 2007-07-30 2010-12-09 Healor Ltd. Pharmaceutical Compositions for treating wouds and related methods
US20090291066A1 (en) * 2008-05-22 2009-11-26 Apostolos Pappas composition and method of treating facial skin defect
US20090291986A1 (en) * 2008-05-22 2009-11-26 Apostolos Pappas Composition and method of treating facial skin defect
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
BRPI1008752B1 (pt) 2009-02-16 2020-02-11 Nogra Pharma Limited Compostos alquilamido, composições farmacêuticas e usos dos mesmos
CN103800903A (zh) * 2009-02-24 2014-05-21 希尔洛有限公司 用于治疗痤疮和其它病症的内脂素治疗药物
AR073505A1 (es) * 2009-09-10 2010-11-10 Monte Verde S A Composiciones y metodos para el tratamiento de enfermedades proliferativas
AU2011204425A1 (en) 2010-01-11 2012-08-02 Healor Ltd. Method for treatment of inflammatory disease and disorder
US20110274776A1 (en) 2010-05-07 2011-11-10 Michael Anthonavage Compositions comprising extracts of southernwood and an amine compound
US20110274775A1 (en) * 2010-05-07 2011-11-10 Michael Anthonavage Extracts of southernwood and topical uses thereof
ES2397889B1 (es) 2011-03-25 2014-02-07 Lipotec, S.A. PÉPTIDOS MODULADORES DE PGC-1Alfa.
JP6301844B2 (ja) 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
KR20150002819A (ko) 2012-04-18 2015-01-07 노그라 파마 리미티드 락토스 불내증의 치료 방법
FR3049864A1 (fr) 2016-04-06 2017-10-13 Naturex Extrait vegetal issu d'une plante du genre aerva, composition le contenant et utilisation dudit extrait vegetal
CN113825739A (zh) 2019-02-08 2021-12-21 诺格拉制药有限公司 制备3-(4’-氨基苯基)-2-甲氧基丙酸及其类似物和中间体的方法
IT202000027489A1 (it) * 2020-11-17 2022-05-17 Mauro Michele Maria Picardo Attivatori selettivi dei recettori attivati da proliferatori peroxisomiali (PPARs) per il trattamento della vitiligine
CN116548385B (zh) * 2023-04-20 2023-10-27 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 自发型系统性红斑狼疮动物模型的构建方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014824A1 (en) * 1988-01-14 1990-12-13 Anders Frithz Use of essential fatty acids for the preparation of a drug for the treatment of eczema
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5443844A (en) * 1992-12-03 1995-08-22 Mcdaniel; William R. Linoleic acid preparations for topical treatment of acne vulgaris
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
SE9403158D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab New use of prostaglandins
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
WO1998008089A1 (en) * 1996-08-23 1998-02-26 Arch Development Corporation Identification of activators and inhibitors of sebum formation
EP0948324B1 (de) * 1996-12-11 2003-11-12 Dana-Farber Cancer Institute, Inc. Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
AU5928898A (en) * 1997-01-24 1998-08-18 Regents Of The University Of California, The Use of fxr, pparalpha and lxralpha activators to restore barrier function, promote epidermal differentiation and inhibit proliferation
US6060515A (en) * 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production

Also Published As

Publication number Publication date
NO325171B1 (no) 2008-02-11
EP1041977A1 (de) 2000-10-11
JP3773790B2 (ja) 2006-05-10
DE69839815D1 (de) 2008-09-11
FR2773075A1 (fr) 1999-07-02
WO1999034783A1 (fr) 1999-07-15
JP2002500179A (ja) 2002-01-08
NO20003414L (no) 2000-08-31
CA2314607A1 (fr) 1999-07-15
BR9815340A (pt) 2000-10-31
EP1041977B1 (de) 2008-07-30
NO20003414D0 (no) 2000-06-29
AU745187B2 (en) 2002-03-14
ES2310019T3 (es) 2008-12-16
US6403656B1 (en) 2002-06-11
CA2314607C (fr) 2009-02-03
FR2773075B1 (fr) 2000-05-05
AU2057599A (en) 1999-07-26
NZ505089A (en) 2002-12-20

Similar Documents

Publication Publication Date Title
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69829412D1 (de) Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
ATE354372T1 (de) Verwendung von mif-antagonisten zur krebstherapie
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ES2143611T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteinasas.
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE285794T1 (de) Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE69736180D1 (de) Behandlung von manischen erkrankungen
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE60020591D1 (de) Benzenoidderivate von 15-hydroxyeicosatetraensäure und verfahren zur verwendung zur behandlung des trockenen auges

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties